Entresto Approval History
FDA Approved: Yes (First approved July 7, 2015)
Brand name: Entresto
Generic name: sacubitril and valsartan
Dosage form: Tablets
Previous Name: LCZ696
Company: Novartis Pharmaceuticals Corporation
Treatment for: Heart Failure
Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination indicated:
- to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. Entresto is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
- for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
Development History and FDA Approval Process for Entresto
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.